Tel. : 01 45 33 67 17 / E-mail : coger@coger.fr
AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
Ajouter au panier
Le produit a été ajouté au panier Le stock est insuffisant. unités ont été rajoutées au panier Total:
|
Stock épuisé.
En rupture de stock
|
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
|
photos non contractuelles
Product description: Polyclonal Antibody. Recognizes the Human protein. Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol. The human Catecholamine-Sulfating Phenol Sulfotransferase (CSPS) is the only sulfotransferase that catalyses the sulfation of catecholamins, in particular the neurotransmitter dopamine, with high activity. CSPS is required for stimulation by Mn2+ of the sulfating activity and expressed in the human intestine, brain, platelet and other tissues. In the brain it may play a role in regulating the levels of dopamine. It also serves as a detoxifying function in the intestine, where it may detoxify potentially lethal dietary monoamines. Catalyzes the sulfate conjugation of phenolic monoamines (neurotransmitters such as dopamine, norepinephrine and serotonin) and phenolic and catechol drugs.
Alternate Names/Synonyms: STM; M-PST; HAST3; TL-PST; SULT1A3; EC=2.8.2.1; ST1A3/ST1A4; Sulfotransferase 1A3/1A4; Aryl Sulfotransferase 1A3/1A4; Placental Estrogen Sulfotransferase; Thermolabile Phenol Sulfotransferase
Product Type: Polyclonal Antibody
Immunogen: Recombinant human protein purified from E. coli.
Applications: WB
Species Crossreactivity: Human
Formulation: Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Short Term Storage: +4°C
Long Term Storage: -20°C
Shipping: BLUE ICE
Use & Stability: Stable for at least 1 year after receipt when stored at -20°C.
Literature References: 1) Pai, T.G. et al. (2003) J. Biol. Chem. 278, 1525-1532. (General)2) Pai, T.G. et al. (2002) J. Biol. Chem. 277,43813-43820. (General)3) Coughtrie, M.W.H. (2002) Pharmacogenomics J. 2, 297-308. (General)
Alerte
Veuillez saisir les champs obligatoires! |